Mumbai, Dec 24 (UNI) City-based Elder Pharmaceuticals, a Rs 500 crore company, has recently signed an in-licensing agreement with Italy-based GNOSIS.
Under the terms of the agreement, GNOSIS has licensed an anti-osteoarthritic nutritional supplement S-Adenosyl Methionine (SAMe), and will supply the product in finished form that will be marketed in India by Elder Pharmaceuticals under the trademark 'SAMPURE', a release said.
GNOSIS is an advanced biotech company. Its range of products include nutraceuticals in the management of chronic disorders like osteoarthritis, osteoporosis and liver disorders.
Osteoarthritis is one of the most prevalent joint disorders, especially in middle-aged and elderly people. Since the proportion of older people in our population is continually rising, osteoarthritis is becoming an increasingly important health problem.
Currently, the market for anti-arthritic products in India is around Rs 600 crore and is showing a good growth, the release informed.
Elder Pharmaceuticals is a mid-sized company that manufactures and markets ethical medicines as well as consumer products such as Tiger Balm and FairOne. Apart from its own brands like Shelcal, it has a number of in-licensing arrangements with more than 25 international healthcare companies, wherein, it manufactures and markets those products under the license of the originator company, the release added.